Search Within

Ritika Kundra

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (57)
  2. Meeting Abstract (27)
Groups
  1. GSK Faculty (84)
  2. Human Oncology and Pathogenesis Program (84)
  3. Epidemiology and Biostatistics (82)
  4. Center for Molecular Imaging and Biotechnology (CMIB) (81)
  5. Computational Oncology Service (79)
  6. Department of Pathology and Laboratory Medicine (66)

More Groups

People
  1. Nikolaus Schultz (79)
  2. Jianjiong Gao (43)
  3. Hongxin Zhang (41)
  4. David Solit (39)
  5. Michael Berger (39)
  6. Marc Ladanyi (32)

More People

Years
  1. 2025 (3)
  2. 2024 (11)
  3. 2023 (5)
  4. 2022 (9)
  5. 2021 (9)
  6. 2020 (18)

More Years

Publications
  1. Cancer Research (13)
  2. Journal of Clinical Oncology (13)
  3. Nature Communications (10)
  4. Cancer Discovery (8)
  5. Clinical Cancer Research (6)
  6. Nature (5)

More Publications

Publishers
  1. American Association for Cancer Research (28)
  2. Nature Publishing Group (20)
  3. American Society of Clinical Oncology (18)
  4. Cell Press (6)
  5. Elsevier Inc. (2)
  6. Springer (2)

More Publishers

Results (84)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Emergence of RTK/RAS/PI3K pathway alterations in trastuzumab-refractory HER2-positive esophagogastric (EG) tumors
    Meeting Abstract

    Janjigian, Y. Y.; Sanchez-Vega, F.; Tuvy, Y.; Bouvier, N.; Riches, J. C.; Margolis, M.; Millang, B. M.; Scott, S. N.; Kundra, R.; Castel, P.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • OncoKB: Annotation of the oncogenic effect and treatment implications of somatic mutations in cancer
    Meeting Abstract

    Chakravarty, D.; Phillips, S. M.; Gao, J.; Kundra, R.; Zhang, H.; Rudolph, J. E.; Yaeger, R. D.; Soumerai, T.; Nissan, M. H.; Chandarlapaty, S.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Clinical next generation sequencing (NGS) of esophagogastric (EG) adenocarcinomas identifies distinct molecular signatures of response to HER2 inhibition, first-line 5FU/platinum and PD1/CTLA4 blockade
    Meeting Abstract

    Janjigian, Y. Y.; Sanchez-Vega, F.; Jonsson, P.; Tuvy, Y.; Bouvier, N.; Riches, J.; Kundra, R.; Ku, G.; Hechtman, J. F.; Kelsen, D.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Genetic determinants of cisplatin resistance in patients with advanced germ cell tumors
    Journal Article

    Bagrodia, A.; Lee, B. H.; Lee, W.; Cha, E. K.; Sfakianos, J. P.; Iyer, G.; Pietzak, E. J.; Gao, S. P.; Zabor, E. C.; Ostrovnaya, I.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save